(Q38839762)

6 September 2017

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study (English)

1 reference

ORCID Public Data File 2021

6 September 2017

1 reference

1 reference

1 reference

author name string

Polaris Observatory HCV Collaborators

series ordinal

1

1 reference

6 September 2017

16 December 2016

1 reference

The lancet. Gastroenterology & hepatology

6 September 2017

1 reference

6 September 2017

2

1 reference

6 September 2017

3

1 reference

6 September 2017

161-176

1 reference

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Acute hepatitis C: management in the rapidly evolving world of HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Global distribution and prevalence of hepatitis C virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Hepatitis C therapy: Looking toward interferon-sparing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Extrahepatic morbidity and mortality of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Global epidemiology and genotype distribution of the hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

The global burden of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Evolving epidemiology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Application of a Technique for Research and Development Program Evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930181-9

7 January 2021

10.1016/S2468-1253(16)30181-9

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

28404132